Navratil Tomas, the Chief Development Officer of Glaukos Corp, has disclosed multiple stock transactions in a recent SEC filing. This update is significant as it details changes in ownership stakes of the company, which operates in the surgical and medical instruments industry.

According to the filing dated November 3, 2026, Tomas executed several transactions on October 30, 2026, involving the acquisition and disposal of Glaukos shares. These transactions are notable as they reflect ongoing adjustments in Tomas's ownership level, which could impact investor sentiment and corporate governance.

Background

Navratil Tomas is associated with Glaukos Corp, a company identified under the Central Index Key 0001192448. Glaukos operates within the surgical and medical instruments industry, focusing on innovative solutions for eye care. The company has been publicly traded and is known for its commitment to developing advanced technologies.

What the Filing Says

The SEC filing reveals that Tomas acquired a total of 4,181 shares at $55 each and 8,788 shares at $85.94 each. Additionally, he disposed of shares in multiple transactions, with notable sales of 10,221 shares at $237.54 and 12,836 shares at $238.56. Following these transactions, Tomas's total shares owned decreased to 71,543.

Impact

These transactions may affect various stakeholders, including investors and corporate governance at Glaukos. As the Chief Development Officer, Tomas's actions could signal confidence or concerns regarding the company's future performance and strategy.

What's Next

The filing does not say what happens next.